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Natural killer T-cells,with an invariantT-cell antigen receptor a-chain (iNKTcells), areunique
and conserved subset of lymphocytes capable of altering the immune system through their
rapidandpotent cytokine responses.Theyare reactive to lipidantigenspresentedby theCD1d
molecule, anantigen-presentingmolecule that isnothighly polymorphic. iNKTcell responses
frequently involvemixturesof cytokines thatwork against eachother, and therefore attempts
are underway to develop synthetic antigens that elicit only strong interferon-gamma (IFNg) or
only strong interleukin-4 responses but not both. Strong IFNg responses may correlate with
tighter binding to CD1d and prolonged stimulation of iNKT cells, and this may be useful for
vaccine adjuvants and for stimulating anti-tumor responses. iNKT cells are self-reactive
although the structure of the endogenous antigen is controversial. By contrast, bacterial
and fungal lipids that engage the T-cell receptor and activate IFNg from iNKT cells have been
identified from both pathogenic and commensal organisms and the responses are in some
caseshighly protective frompathogens inmice. It is possible that theexpandingknowledgeof
iNKT cell antigens and iNKT cell activation will provide the basis for therapies for patients
suffering from infectious and immune diseases and cancer.Introduction
General background
Initially described in mice [1], natural killer T-cells (NKT cells)
have characteristics of both innate and adaptive immune
cells. In mice, they were originally identified as cells thatmental Immunology, La J
ax: þ1 858 752 6990.
berg).
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mons.org/licenses/by-ncexpress NK 1.1, a marker for NK cells, which are a type of
innate lymphocyte, expressed together with a ab T-cell re-
ceptor (TCR), characteristic of adaptive immune cells. It is now
known that all NKT cells do not express NK 1.1, and a subset of
these lymphocytes expresses an invariant TCR a-chain that
imparts a particular glycolipid specificity that is described
further below. Cells with this phenotype were later confirmed
to be present also in humans [2]. As in the mouse, the humanolla Institute for Allergy and Immunology, 9420 Athena Circle, La
ces provided by Elsevier B.V. This is an open access article under
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Fig. 1 e CD1d lipid binding pocket showing A0 and F0 grooves
with a-galactosylceramide bound to CD1d for reference.
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case, CD161, and it also expresses the abTCRwith an invariant
a-chain that shares significant homology with its mouse
counterpart [3]. Comprising approximately 1% of peripheral
lymphocytes in mice, NKT cells numbers in the peripheral
blood mononuclear cells of humans tend to be less frequent,
with a wide variation ranging from under 0.01% to 1% in
healthy donors [4]; however, using CD161 and TCR expression
as a definition of NKT cells, the frequency is much higher.
Because they express the ab TCR, it was originally assumed
that NKT cells would recognize peptides, similar to conven-
tional T-lymphocytes that recognize peptides presented by
major histocompatibility complex (MHC)-encoded antigen
presenting proteins. Although early data and some recent
data [5,6] indicated that NKT cells may be able to recognize
peptides, it has been widely confirmed that NKT cells recog-
nize and respond to lipids, mostly glycolipids. These antigens
are presented not by MHC-encoded molecules but by CD1d, a
related protein encoded outside the MHC gene complex [7].
This reviewwill provide a brief overview of NKT cells, some of
their known antigens and properties of the CD1d molecule.
Type I and Type II natural killer T-cells
Although thereareT-lymphocyteshavingdifferent specificities
that express NK receptors, NKT cells are now generally defined
as T-cells that recognize CD1d. The most commonly studied
NKT cells are invariant NKT cells (iNKT cells) or Type I NKT
cells, which express a nearly fixed or invariant TCR a-chain
encoded by a Va14-Ja18 rearrangement. This a-chain is co-
expressed most frequently with a Vb8.2, Vb7, or Vb2 TCR b-
chain inmice. In humans, the Type I NKT cell TCR is formed by
a nearly fixed Va24-Ja18 (TRAV1-2-TRAJ18) rearrangement
pairedwith a Vb11 b-chain. Themouse and human invariant a-
chains are true homologs, as are human Vb11 and mouse Vb8.
As a consequence; the specificity of mouse and human iNKT
cells is highly conserved. This Type I NKT cell TCR has a
conserved parallel binding motif radically different than the
binding orientation of the TCR of mainstream CD4 or CD8 T-
cells [8]. Type II NKT cells recognize CD1d aswell; however, the
a-chain is not highly restricted in diversity. Therefore, they donot have a single specificity, and they have been much less
studied [9]. Here,wewill focus onType INKT cells or iNKTcells.
Biological response of invariant natural killer T-cells
iNKT cells are very rapid responderswhen stimulated through
their TCR, providing a cytokine burst within 90 min of in vivo
stimulation [10]. Though TCR recognition of a lipid antigen
presented by CD1d [Fig. 1], iNKT cells can induce a wide range
of cytokines including T-helper Type 1 (Th1), T-helper Type 2
(Th2), and other responses. Activated iNKT cells not only
secrete these cytokines but also induce other cells to secrete
cytokines. The results from a number of studies demonstrate
that the totality of the iNKT cell-induced immune response is
dependent on the structure of the lipid antigen that is pre-
sented and recognized. Certain lipid antigens cause the pro-
duction of predominately Th1 cytokines such as interferon-
gamma (IFN-g) and tumor necrosis factor, and other lipids
lead to a more Th2 skewed pattern of cytokines that includes
interleukin (IL-4), IL-5, and IL-13 [11].
a-Galactosylceramide
The most studied glycolipid that activates iNKT cells, also the
first discovered, is a-galactosylceramide (aGalCer) [Figs. 1 and
2]. This is sometimes considered Th0 skewing lipid as iNKT
cells that respond to this lipid robustly produce both IFN-g and
IL-4. aGalCer was originally identified by the Kirin Pharma-
ceutical Company in a screen of natural extracts for sub-
stances that prevent metastases of the mouse B16melanoma,
and it was shown to reduce liver metastases [12]. The struc-
ture was then synthesized and optimized by medicinal
chemistry using the tumor metastases assay [13,14]. aGalCer
has a-linked galactose, a phytosphingoid base chain with 18
carbons, and an acyl chain containing 26 carbons. aGalCer has
not yet proven highly successful in human cancer studies,
whichmay be due to the fact that it leads to both Th1 and Th2
cytokine responses [15,16]. These opposing responsesmay not
promote an optimal anti-tumor response, which is more Th1-
dependent. There are other explanations for reduced efficacy
including the lower affinity of aGalCer/CD1d complexes for
the human TCR compared to the mouse TCR [17]. For these
reasons, there have been extensive efforts to develop other
iNKT cell-activating lipids that can skew the cytokine
response, especially in a Th1 direction. In addition, the type of
antigen-presenting cell (APC) targeted may be critical, and in
clinical trails, transfer of dendritic cells (DC) incubated with
aGalCer generated a more robust iNKT cell response than
aGalCer alone [16,18,19]. Continuing efforts to develop more
effective glycolipids, delivery systems, and cell-based thera-
pies using aGalCer remain underway.
CD1d
CD1d antigen-presenting molecule is a member of the family
of CD1 proteins. This family is divided into two groups: Group
1 CD1 proteins (CD1a, CD1b, and CD1c) and Group 2 CD1
(CD1d) [20]. There is also a third, intermediate group member
(CD1e). Whereas CD1a, CD1b, CD1c, and CD1d are found on
the cell surface; CD1e is an intracellular protein that facilitates
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found in humans and most other mammals; however, the
mouse genome contains only two copies of the CD1d gene and
no Group 1 CD1 proteins.
CD1d has a heterodimeric structure similar to MHC Class I
antigen presenting molecules, with a heavy chain having
three extracellular domains and a conserved b2-microglobulin
subunit [22]. However, whereas MHC Class I molecules have
shallow binding grooves capable of binding peptides that are
typically nine amino acids in length; CD1d has amuch deeper,
narrower, and more hydrophobic groove containing two
pockets, delineated as A0 and F0 [Fig. 1]. This groove is perfectly
suited to bind glycosphingolipids (GSLs) that have two hy-
drophobic chains that can anchor deeply within it. The phy-
tosphingoid base chain of GSLs is localized to the smaller F0
pocket, whereas the amide-linked fatty acid chain binds in the
A0 pocket. Within the A0 pocket, the lipid chain must curl
around a central point created by Cys12 and Phe70 [21]. The
binding of the lipid chains within CD1d exposes the saccha-
ride head group that is recognized and forced into a fixed
orientation by the iNKT cell TCR [23].
CD1d is synthesized in the endoplasmic reticulum (ER) and
binds to self-phospholipids that allow it to traffic to endo-
somal compartments and the cell surface [21]. It has a
tyrosine-containing cytoplasmic tail motif that mediates
internalization to endosomes and eventually to lysosomes
before recycling back to the cell surface. Exchange of self-
antigens obtained in the ER with exogenous glycolipids and
with self-lipids involved in the positive selection of iNKT cells
in the thymus occurs within endosomal compartments
[24,25], and for some exogenous antigens, also on the cell
surface [26]. CD1d is expressed on a wide variety of hemato-
poietic series cells including B-cells, DC, macrophages, Lang-
erhans cells, monocytes, T-cells, and iNKT cells [27]. Some
nonhematopoietic cells including hepatocytes and intestinal
epithelial cells also express it [28,29]. Data indicate that DCs
are the key activators of iNKT cells for exogenous glycolipids,
except that various types of macrophages are important for
presenting glycolipids in particulate form such as on beads or
in liposomes [30]. Recently, the CD8aþ DEC-205þ DC subset
was identified as the APC type responsible for inducing both
Th1 and Th2 responses [31]. According to these findings,
increased expression of cell surface markers Rae-1 and CD86
by APCs leads to a Th1 cytokine profile while increased APC
expression of PD-L2 serves to promote a Th2 cytokine profile
[31].Synthetic antigens
Head group modifications
The hydrophobic chains of iNKT cell lipid antigens are usually
bound deep within the pockets of CD1d, and a polar head
group is exposed for recognition by the iNKT cell TCR. The
CD1dmolecule stabilizes this head group through interactions
with a1 and a2 helices [22]. In humans, position 153 of the a2
helix is a tryptophan amino acid, instead of a glycine in the
homologous position (155) of mouse CD1d. Tryptophan, being
a much bulkier amino acid, shifts the sugar head group into a
slightly different position [23,32]. This is the main distinctionbetween the structures of the GSL-CD1d complexes expressed
by mice and humans.
Contacts between Asp153 and Thr156 of mouse CD1d and
the 20 and 30-hydroxyls of the aGalCer saccharide head group
as well as the aGalCer O-glycosidic oxygen are important for
ordering the sugar head group [33,34]. Because iNKT cell TCR
recognizes the galactose head groups of GSLs, it is not sur-
prising that altering this head group had deleterious effects on
TCR binding. Modifications of the 20, 30, or 40 positions,
particularly 20 diminished iNKT cell responses and TCR bind-
ing [35,36]. For example, while aGalCer and a-glucosyl cer-
amide (aGluCer) could both activate iNKT cells, which
indicated that the axial versus equatorial orientation of the 40-
hydroxyl group is not critical; aGalCer was the most potent
antigen. In contrast, a-mannosyl ceramide (aManCer) did not
activate iNKT cells, indicating that the equatorial 20-hydroxyl
is critical [37]. Additional studies demonstrated the impor-
tance of the 20-hydroxyl group in TCR recognition, as synthetic
analogs of aGalCer with modifications of this position lacked
antigenic activity [38]. The 30 position is more permissive as
modifications at this position decreased but did not
completely diminish activity [38e40]. Modifications of the 60
position are the most tolerated. This makes sense as crystal
structures of the CD1d-lipid-TCR complex show that the 60
position does not make contacts with the TCR [17,41e43].
Tolerance for modifications at the 60 position were revealed in
a study that compared responses to Gal (a1-2) GalCer with Gal
(a1-6) GalCer, which are both GSLs with a disaccharide as
opposed to monosaccharide head groups. While Gal (a1-2)
GalCer required carbohydrate processing to remove the ter-
minal galactose in order for antigenic activity, Gal (a1-6)
GalCer did not [44]. Indeed, modification of the 60-hydroxyl
proved to be beneficial when PBS57, a 60-deoxy-60-acetamide
aGalCer analog, was synthesized [45]. PBS57 was not only
more easily solubilized than aGalCer, and it also induced a
more potent in vivo cytokine response [46]. The 60 position is
permissive for the addition of other bulky chemical groups as
exemplified by the napthylurea aGalCer molecule (NU-aGC)
[Figs. 2 and 3] [47]. NU-aGC causes a robust Th1 cytokine
response and reduces tumor metastases in mice even more
effectively than aGalCer. It is very likely that NU-aGC binds in
a more stable fashion to CD1d than aGalCer as the NU group
serves as a “third anchor” of the lipid for binding to the CD1d
molecule. It binds on top instead of deep in the CD1d groove,
but without impeding the TCR [48]. Other 60 modifications
such as NC-aGalCer, 4ClPhC-aGalCer, and PyrC-aGalCer are
also antigens that induce strong Th1 cytokine responses,
correlated with a marked reduction of B16 melanoma metas-
tasis to the liver [49]. PyrC-aGalCer, the most potent of these
lipids, also shows novel and increased contacts with the both
CD1d and the iNKT cell TCR. The 60 modifications have also
served as tools for labeling GSLs with biotin or fluorophore,
which has permitted analyses of their progress through
endosomal compartments in cells [50].
Other synthetic alterations have been used to create a-
carba-GalCer analogs [51]. In 2009, carbasugar and cyclitol
analogs of aGalCer were generated, and another three ana-
logs, RCAI-56 (a carba-a-D-galactose analog), RCAI-59 (a 1-
deoxy-neo-inositol analog), and RCAI-92 (a 1-O-methylated
analog), also were found to be Th1 skewing lipids [52]. The a-
Fig. 2 e Some representative Th1 and Th2 cytokine skewing lipids compared to a-galactosylceramide.
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galactose replaced with a methyl group, was shown to be an
effective Th1 skewing molecule [53]. The authors proposed
twomechanisms for this response. First, themethylene group
replacing the oxygen atom interaction of the sugar head group
makes the lipid less susceptible to degradation by hydroxyl-
ation, therefore allowing it to be presented for longer. Second,
the oxygen of aGalCermay lead to a repulsive interaction with
Pro28 of the TCR a-chain whereas the carbon of a-carba-
GalCer would lead to an enhanced hydrophobic interaction
[53]. This lipid alsowas tested in collagen-induced arthritis, an
autoimmune model of rheumatoid arthritis in mice, and it
was shown to provide protection against Th17-mediatedautoimmune arthritis through the induction of Th1 cyto-
kines [54].
HS44 is another GSL with head group modifications of
aGalCer that induces a strong Th1 cytokine response. HS44 is
an aminocyclitol molecule in which the sugar head group is a
carba cyclitol ring that mimics glucose instead of galactose,
and which has the O-glycosidic linkage replaced with an
amide group [55]. Structural analysis and binding assays by
surface plasmon resonance showed that when bound to CD1d
this compound had a 14-fold weaker interaction with the
iNKT cell TCR compared to aGalCer. Despite this, it caused a
strong Th1 cytokine response and was effective at preventing
tumor metastases [56].
Fig. 3 e Two T-helper Type 1 skewing lipids crystallized in complex with mouse CD1d and the invariant Natural Killer T-cell
receptor. PDB files: napthylurea, a-galactosylceramide (PDB code: 3QUZ), SMC (PDB code: 3TVM).
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As previously mentioned [55], the O-glycosidic linkage of
aGalCer can be altered, and in doing so, can lead to some
unique properties. In 2003, the oxygen bond was altered to a
CH2, theorizing that this GSL would be more resistant to a-
galactosidase-mediated catabolism [57,58]. This compound,
referred as C-glycoside [Fig. 2], was the first glycolipid shown
to induce a strong Th1 cytokine response in mice [59], but it
did not stimulate human iNKT cells very strongly. The ternary
structure of C-glycoside/CD1d complexes bound to the iNKT
cell TCR demonstrated the importance of hydrogen bonding of
the oxygen in the O-glycosidic linkage to CD1d [48,60].
Without this linkage, the galactose headgroup was in a sub-
optimal orientation when bound to CD1d, resulting in a lower
TCR affinity compared to aGalCer/CD1d complexes.
Several C-glycoside analogs with a double bond were syn-
thesized to try to generate a glycolipid providing a more fixed
orientation of the galactose headgroup, in the expectation
that this would activate iNKT cells to produce a strong Th1
response [61]. One of these, GCK127 had an E-olefin linker
instead of a CH2 glycosidic linkage. This molecule activated
both mouse and human iNKT cells, albeit it was less potent
than aGalCer [61]. The O-glycosidic linkage has also beenmodified by replacing the oxygen with a sulfur atom. The a-S-
GC molecule induced a more Th2 skewed cytokine profile in
mice and did not lead to increased survival in a tumor model
[62]. A sulfur linkage was proposed to have a similar confor-
mation to an oxygen bond, because although a sulfur atom is
larger than oxygen, the bond angle is less than an O-glycosidic
linkage and a thioglycosidic linkage would be less susceptible
to enzymatic cleavage [63]. However, in vivo studies in mice
indicated that a-S-GC did not lead to iNKT cell proliferation or
cytokines. The authors proposed that the a-S-GC compound
would lack some key hydrogen bonds when bound to CD1d,
but this remains a conjecture. Another group synthesized the
same compound and showed that although it did not stimu-
late mouse iNKT cells, it could activate human iNKT cells,
causing cytokine secretion and iNKT cell-induced maturation
signals in human DCs [64]. This is an intriguing counter
example of species specificity of iNKT cell reactivity,
compared to C-glycoside, which only works to activate mouse
iNKT cells but not those from humans.
Lipid chain modifications
The sphingoid base is a defining property of the GSL antigens
that activate iNKT cells. The most commonly found
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18 chains; however, the number of carbon lengths can range
from 14 to more than 27, and the sphingosine can have a wide
variety of saturation levels and branched modifications [65].
The phytosphingosine of aGalCer [Fig. 2], with a hydroxyl
group at C-4, differs from the more common natural sphin-
gosine, which typically contains a trans double bond between
C-4 and C-5. OCH is a compound with a phytosphingosine
shortened by several carbon atoms [Fig. 2] [66]. This lipid an-
tigen induced a more IL-4 dominated or Th2 profile. When
injected into mice, OCH was shown to reduce the symptoms
of experimental autoimmune encephalomyelitis, a mouse
model of multiple sclerosis [66]. The further shortening of the
sphingoid chain also led to a Th2 cytokine profile [67].
Different alterations of the sphingoid base can have an
opposite polarizing effect on the cytokine response. For
example, SMC124 is a synthetic Th1 skewing GSL similar to
aGalCer but with a sphingoid base chain length increased to 22
linear carbonswith the addition of a cyclopropyl group at C11-
12 [Figs. 2 and 3]. It was designed tomimic partially a naturally
occurring GSL called plakoside A [68]. The results from struc-
tural studies of OCH and SMC124 bound to mouse CD1d sug-
gest that the length of the lipid chain packed within the F0
pocket of CD1dmay alter the presentation of the GSL [68]. The
longer, bulkier chain of SMC124 may anchor the lipid more
deeply within the antigen-presenting molecule, thereby pro-
longing antigen presentation, which may, for reasons that
have not been completely elucidated, contribute to Th1 cyto-
kine skewing. Conversely, OCH does not have a long chain to
anchor CD1d and may have a reduced antigen presentation
time.
The acyl chain of a number of synthetic GSL antigens is
typically longer than the sphingoid base. For aGalCer, the acyl
chain is an unbranched and fully saturated 26 carbons long.
C20:2 is a GSL antigen containing a di-unsaturated and
shorter, 20 carbon, and acyl chain [Fig. 2] [69]. This compound
was identified in a screen of multiple aGalCer analogs with
shorter acyl chains, all of which induced an enhanced Th2
cytokine profile [67]. The decrease in the carbon chains of the
lipid, either in the acyl chain or in the sphingoid base, is
proposed to destabilize the interactions between the lipid and
CD1d. Indeed, when the lipid chains become too short, the
interaction of the lipid and the CD1d is too unstable for any
stimulation of iNKT cells [67]. Conversely, the elongation of
the carbon chains, or the addition of bulky groups to the acyl
chain, caused a Th1 profile that may be due to stabilization of
the CD1d/lipid interaction. For example, the addition of an
aromatic group to the terminus of the fatty acid created a
potent IFN-g inducing lipid in human cells [70]. 7DW8-5,
which contains a C10 length fatty acyl chainwith a fluorinated
benzene ring at the end, is planned for use in clinical trials as
an adjuvant for a malaria vaccine [Fig. 2] [71]. 7DW8-5 was
shown to exhibit a higher binding affinity to both mouse and
human CD1d molecules than aGalCer, resulting in a more
potent stimulatory activity for iNKT cells [72]. Ultimately,
7DW8-5 could display a stronger adjuvant effect than aGalCer
for malaria vaccine testing in mice [72] and nonhuman pri-
mates. EF77 is a companion lipid to SMC124 because it is also
partially modeled after aGalCer and plakoside A. EF77 is
identical to aGalCer but with an elongated acyl chaincontaining a cyclopropyl group. Like SMC124, EF77 also
induced a strong Th1 cytokine response in mice [68]. Both of
these GSL antigens were shown to form more stable com-
plexes in vivo with CD1d on the surface APCs, at least when
compared to aGalCer, consistent with the hypothesis that
stronger or prolonged antigen interactions with CD1d favor
IFN-g production in vivo. [68].
Endogenous ligands
When the initial antigens for iNKT cells were discovered, it
was predicted that the linkage of the sugar to the lipid could
only be a-anomeric, and a b-linkage would not lead to iNKT
cell activation [37,73]. This was presumed as logical as the a-
anomeric form as well as D-glycosylceramides were not
thought to be detected in mammals and are therefore
“foreign” epitopes. However, the analysis of iNKT cell differ-
entiation in the thymus indicated that there had to be a self-
ligand that could positively select these cells. A b-Linkage of
sugar to the ceramide lipid does occur naturally in mammals,
b-anomeric GSLs are part of cellular membranes [74,75]. b-
linkages therefore were considered to be candidates for the
major self-ligands [76]. Mice lacking bGalCer synthase, and
thus lacking bGalCer, have normal iNKT cell development [77],
and while mice treated with this compound have decreased
iNKT cells in vivo, there was no detectable cytokine signal [78].
bGluCer, having glucose instead of galactose, is both an
anabolic and catabolic GSL pathway metabolic intermediate
[79], and it decreases in vitro iNKT cell proliferation [80] and is
accumulated in patients with Gaucher's disease, which have
an increase in iNKT cells [81]. Surprisingly, while aManCer
fails to activate iNKT cells, bManCer is an iNKT cell ligand
capable of inducing a protective anti-tumor response [82].
This anti-tumor ligand operates through the induction of
TNFa and nitric oxide, without IFN-g, and it does not induce
anergy, a side effect of some other strong iNKT cell ligands
[83].
Because iNKT cells originate in the thymus, it was
assumed that there must be some endogenous ligand(s) that
participate in their positive selection. The hunt for endoge-
nous ligands turned up several candidates including, iso-
globotrihexosylceramide (iGb3), plasmalogen lysophos
phatidylethanolamine [84], lysophosphatidylcholine, lyso-
phosphatidylethanolamine, phosphatidylinositol, phospha-
tidylcholine, phosphatidylserine, phosphatidic acid bGluCer,
bGalCer [85], and even a peptide from mouse collagen
[6,75,81,86e89]. The structures of some of these are shown
in [Fig. 4] iGb3, the first identified self-ligand [86], was crys-
tallized, and it was shown that the mouse CD1d molecule
can bind iGb3 [Fig. 5] [90]. When CD1d is loaded with iGb3, it
forms a complex with the iNKT cell TCR in which the lipid-
proximal sugar is moved into a conformation similar to a-
linked ligands. The terminal sugar of iGb3 forming novel
contacts with CD1d [Fig. 5] [91,92]. However, the validity of
such a compound as an endogenous ligand has been clou-
ded by reports that suggest mice lacking iGb3 synthase,
essential for iGb3 formation, still have a normal iNKT cell
population [93]. In addition, it has been claimed that human
CD1d cannot present iGb3 because of the glycine-tryptophan
difference mentioned above [94], and iGb3 is not present in
Fig. 4 e Proposed endogenous ligands for invariant natural
killer T-cells. Top: Crystal structures of tri-molecular
complexes and the corresponding glycosphingolipid antigen
structures are indicated. Bottom: Phospholipid-containing
putative self-antigens.
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required self-ligand for iNKT cells. b-Glucosyl ceramide was
identified as another endogenous ligand for iNKT cells. With
a structure very similar to aGalCer, and data indicating that
this lipid accumulated in the presence of a microbial infec-
tion [96], as well as tumor prevention data [97], it seemed
very logical that this ligand could activate iNKT cells. How-
ever, recent data has indicated that the activation of iNKT
cells in this study could be due to contaminating trace a-
anomeric lipids, possibly generated during synthesis of b-
glycolipids [98,99]. Regardless of the antigen, it is entirely
possible that these self-ligands serve as not only a selection
mechanism but also a means to get over an activation
threshold when iNKT cells are activated by cytokines such
as IL-12, IL-18, or IFN-1 [100e103].
Bacterial antigens for invariant natural killer T-cells
Mycobacterium tuberculosis
The first lipid antigens identified for any T-lymphocytes were
lipids fromMycobacteria presented by Group 1 CD1molecules
[104e106]. These bacteria have an unusual outer waxy
coating, comprised of different lipids, which is used to evade
immune clearance. A screen of CD1d bindingmammalian and
Mycobacterium lipids identified phosphatidylinositol tetra-
mannoside (PIM4) [107] isolated from a related bacterium,
Mycobacterium bovis bacillus, a cause of bovine tuberculosis.
The structure of a similar lipid, PIM2, bound to CD1d allowed
for modeling of the PIM4 molecule in the CD1d groove [108].
However, a synthetic PIM4 molecule was shown to not stim-
ulate iNKT cells [109], highlighting the need to compare the
outcomes with synthetic and purified lipids. Subsequent work
showed that Type II NKT cells with diverse TCRs could
recognize different phospholipids from Mycobacterium tuber-
culosis. [110].
Sphingomonas spp.
Sphingomonas spp. was the first bacteria unambiguously
shown to have antigens for iNKT cells. Sphingomonas are
commensal bacteria of the human intestine, and there is ev-
idence that commensal bacteria affect the number and func-
tion of iNKT cells [73,111e113]. Although not highly
pathogenic, Sphingomonas includes more than 30 species that
live in a wide variety of environments including soil and
seawater. Sphingomonas paucimobilis is the most pathogenic,
and it may be an opportunistic pathogen associated with
suppression of the immune system [114]. As early as 2000,
purification of GSLs from Sphingomonas bacteria was per-
formed and it was noted that bacterial synthesis of different
lipids can change depending on environmental factors
[115e117]. There is an unusually high presence of GSLs in this
a-Proteobacteria, instead of the LPS that is otherwise
commonly found in Gram-negative bacteria [118]. In 2005,
using both purified and synthetic material, several strains of
Sphingomonas bacteria were shown to have antigens for iNKT
cells including S. paucimobilis, Sphingomonas capsulate, and
Sphingomonas yanoikuyae [73,119]. From these organisms, GSLs
were isolated that had very strong structural similarities to
aGalCer. For example, from S. paucimobilis, GSL-1 was isolated
a-glucuronosylceramide compound, and from S. yanoikuyae a-
Fig. 5 e Induced fit by the invariant natural killer T-cell receptor with iGb3 showing the carbohydrate head group before and
after T-cell receptor engagement. In A, only the sugar linked to the ceramide lipid could be resolved, presumably because the
position of the two distal sugars was not fixed in the crystal. iGB3 before engagement (PDB code: 2Q7Y) and after engagement
(PDB code: 3RZC) shown in comparison to a-galactosylceramide (PDB code: 3HE6).
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lipids are highly similar but differ only in their carbohydrate
head groups; having a glucuronic acid versus galacturonic
acid (GalA). Since their discovery, GSL-10 has been renamed as
GalA-GSL to indicate the presence of GalA [Fig. 6]. This family
of Sphingomonas-derived compounds also contains some with
additional saccharide groups including tri-and tetra-saccha-
rides known as GSL-3 and GSL-4, respectively. While the
monosaccharide-containing GSL antigens activate iNKT cells
in vivo and in vitro, [73,119,120] they are all weaker than
aGalCer. For example, the iNKT cell TCR affinity for GalA-GSL/
CD1d is 50-fold weaker than for the aGalCer/CD1d complex
[23]. The GSLs with oligosaccharide headgroups are not anti-
genic or do not activate as well as their monosaccharide
counterparts, possibly due to a failure of the APCs to reduce
the structures to a monosaccharide form in lysosomal com-
partments [46,121].Fig. 6 e Invariant natural killer T-cell microbial lipids that
have been crystallized in complex with mouse CD1d and the
mouse invariant natural killer T-cell receptor.Borrelia burgdorferi
Whereas Sphingomonas spp. is not considered pathogenic,
another source of iNKT cell antigens is from the pathogenic
spirochete Borrelia burgdorferi. These bacteria, transmitted to
humans by Ioxedes scapularis (deer tick) bites, are the cause of
Lyme disease, which is currently the most common vector-
borne disease in the United States [122]. The immune
response of mice to B. burgdorferi infection is partially CD1d
dependent as a strain of mice resistant to Lyme arthritis had
symptoms when the gene encodingCD1d was deleted [123].
Furthermore, mice lacking CD1d had decreased pathogen-
specific antibodies [124]. B. burgdorferi-induced pathogenesis
was increased in Ja18 deficient mice, which cannot form the
invariant iNKT cell a-chain. In C57BL/6 mice, the absence of
iNKT cells led to increased replication of spirochetes in the
joint, delayed clearance, and arthritis [125,126] while Ja18
deficient mice on the BALB/c background had increased car-
ditis [127]. Analysis of lipids from B. burgdorferi detected a se-
ries of abundant galactosyl diacylglycerols (DAGs) including
BbGL-2 [109]. BbGL-2 was shown to activate iNKT cells in pu-
rified and synthetic forms. BbGL-2 was the first reported iNKT
cell antigen that is not a GSL; it contains a D-galactose
saccharide group with an a-anomeric glycosidic bond and is a
DAG lipid, with lipid chains that vary in length and degree of
saturation. Themost highly potent of these inmice was BbGL-
2c [Fig. 6], with C18:1 oleic acid in the sn-1 position and C16:0
palmitic acid in the sn-2 position [109] [Fig. 6]. Structural
characterization of multiple different DAG antigens showed
how alteration of the lipid chains determines the binding
mode. The sn-1 linked fatty acid is capable of binding to either
A0 or F0 pockets ofmouse CD1d,with C18:1 oleic acid preferring
the A0 pocket [23]. The different bindingmodes determine how
the exposed saccharide group is oriented for recognition by
the TCR. Structural analysis demonstrated that the orienta-
tion of the BbGL-2c allowed for an optimal configuration
compared to another DAG lipid with two unsaturated fatty
acid chains [23]. Interestingly, in humans, the optimal sn-1
and sn-2 fatty acids are different because of the role that the
position 153 tryptophan in the human CD1d a2 helix plays in
orienting the exposed sugar.
Streptococcus pneumonia
Streptococcus pneumonia is a Gram-positive bacterium that not
only leads to pneumonia, but also causes potentially lethal
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shown to be protective in mice following pulmonary
S. pneumonia infection [128], and this protective response was
linked to IFN-g production by the iNKT cells [129]. The lipids of
this bacterium were subjected to electrospray mass spec-
trometry analysis and two highly abundant DAGs were iso-
lated: a monosaccharide linked DAG, a-glucosyldiacylglycerol
(GlcDAG) [Fig. 6], and a disaccharide linked DAG, a-galactosyl
GlcDAG (GalGlcDAG) [130]. Like the B. burgdorferi antigen, the
DAG from S. pneumoniae has a-linked hexose sugar in the sn-3
position but is a glucose rather than galactose. This antigenhas
palmitic acid (C16:0) in the sn-1 position, and a vaccenic acid, a
C18:1 fatty acid with a C11-C12 unsaturated bond, in the sn-2
position. The ternary crystal structure of GlcDAG bound to
mouse CD1d with the iNKT cell TCR engaged shows that the
vaccenicacidallows foranovel conformational changecausing
a re-orienting of the axial 40-hydroxyl group of glucose to allow
for the TCR to engage in a conserved binding motif [131].
Helicobacter pylori
Helicobacter pylori is a common, Gram-negative spiral bacte-
rium that causes stomach problems in some individuals
including gastritis, peptic ulcer, duodenal ulcer, lymphoma,
and gastric cancer [132]. Certain H. pylori lipid extracts have
beenshown toexpand iNKTcells and toplaya beneficial role in
clearing the bacterium [133,134]. This bacterium synthesizes
cholesteryl a-glucosides using host-derived cholesterol.
Although one study presented data indicating that cholesterol
glucosylation allows H. pylori to evade phagocytosis by
macrophages [135], these compounds also were shown to be
recognized by iNKT cells, and the absence of iNKT cells inmice
was correlated with increased H. pylori infection [134]. In a
different study, mice were protected from asthma symptomsFig. 7 e Invariant natural killer T-cell microbial lipids that
currently have not been crystallized in complex with CD1d
and the mouse invariant natural killer T-cell receptor.byadministeringanH. pylori, cholesterol-containing, synthetic
glycolipid called PI57 [Fig. 7] [133], although this compound
activated iNKT cells in both mice and humans, as determined
by immune assays, biochemical analysis of TCR interaction
with the cholesteryl a-glucoside complex with CD1d, and
structural analysis showing how a cholesterol-containing an-
tigen binds to CD1d, have not been reported.
Fungal antigens for invariant natural killer T-cells
Recently, it was reported that Aspergillus fumigatus contains a
glycolipid antigen that can activate iNKT cells. Aspergillus is a
ubiquitous fungus, and although exposure through inhalation
is almost a daily occurrence, the spores or conidia can lead to
infections, most commonly in the lungs and sinuses, and
furthermore, Aspergillus exposure can contribute to asthma
[136]. Previously, it had been shown that iNKT cells were acti-
vated by b-1,3-glucans from Aspergillus, which triggered IL-12
secretion from APCs that mediated the activation of iNKT
cells, butwhich also required recognitionCD1d-presented self-
antigens [137]. In themore recent study implicating amicrobial
lipid in iNKT cell activation, the lipids of the twomost common
strains of Aspergillus, A. fumigatus, and Aspergillus niger were
fractionated and tested against primary iNKTcell lines, and the
GSLasperamideB [Fig. 7]was identifiedasanantigen formouse
and human iNKT cells. Asperamide B is a b-linked gluco-
sylceramide, which is different from any of the previously
described a-linked exogenous ligands. It possesses a 9-methyl-
4,8-sphingadienine chain, commonly found in fungi [65] and a
b-gunsaturated acyl chainwith an ahydroxyl group [138]. Both
purified and synthetic asperamide Bwere able to activate iNKT
cells, and mice exposed to asperamide B experienced airway
hyperreactivity, a feature of asthma, within 24 h [139].
Protozoan antigens for invariant natural killer T-cells
The glucosylphosphoshatidylinositol (GPI) anchors of surface
proteins from Plasmodium falciparum and Typanosoma brucei
could expand iNKT cells, and this expansion was CD1d
dependent [140]. A subsequent study, however, contradicted
the earlier finding that reported that the production of
Plasmodium anti-circumsporozoite IgG was MHC Class II-
independent, and by implication, iNKT cell dependent. These
investigators also reported that GPI anchors could not induce
iNKT cell activation [141]. More recently, a phosphoinositol
antigen known as EhPI [Fig. 7] was isolated from a pool of lip-
opeptidophosphoglycans from Entamoeba histolytica tropho-
zoites and was shown to activate iNKT cells [142]. E. histolytica
can be fatal, especially in the developing world, as it leads to
amoebiasis, a diarrheal disease [143]. There are two isoformsof
EhPI, a and b, with the only difference between thembeing the
acylation of inositol. Only the diacylated EhPIb [Fig. 7] stimu-
lated iNKTcells. This lipid caused IFN-gactivationof iNKTcells
that was dependent not only on CD1d but also on IL-12
production through Toll-like receptor signaling of APCs [142].
Summary
In conclusion, over the past two decades, knowledge about the
specificity of iNKT cells has grown dramatically. Synthetic
b i om e d i c a l j o u r n a l 3 8 ( 2 0 1 5 ) 4 7 0e4 8 3 479agonists have been synthesized that bind with different de-
grees of stability to CD1d and that are able to preferentially
skew the global immune response. Several natural antigens
for iNKT cells have been identified, and they are both self-
antigens that originate from antigen-presenting cells or
foreign antigens from commensal or pathogenic microbes. It
has been shown in several cases that the protective responses
to pathogenic microbes depend on iNKT cell activation. The
iNKT cell TCR can recognize these different structures, which
are mostly glycolipids. A conserved docking motif of the iNKT
cell TCR has been characterized through dozens of structural
studies and is nearly always present, in some cases through a
large accommodation of the antigen. Much work has been
done to understand the mechanism of antigen recognition
and the therapeutic potential of iNKT cells [36,144e146], and
the hope is that this detailed biochemical knowledge can be
harnessed to realize the therapeutic potential of these cells.r e f e r e n c e s
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